*ST announced that it plans to transfer 100% of Jilin Weiming's shares, “recombinant anti-TNFα all-human monoclonal antibody injection” pharmaceutical technology, and “injectable recombinant anti-CD25 human mouse chimeric monoclonal antibody” drug technology through public listing on the Dalian Property Exchange. The initial public listing price was determined based on the underlying historical cost, totaling 559 million yuan, and the final transaction price was determined on a market-based basis. After the transaction was completed, the company no longer held the above shares and pharmaceutical technology. The transaction did not constitute a major asset restructuring. There is uncertainty about the success of the transaction, and it is not yet possible to determine whether it is a related transaction.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.